Mannkind - MNKD - Consider Buying A Few Shares Under $2.00
The announcement that Mannkind has issued a new secondary to raise funds has created a buying opportunity.
Mannkind's insulin drug, Afrezza, could receive F.D.A. approval as early as September,2013 if it is granted "priority review" status.
With $1.6 billion in tax-loss carry forwards and insulin inventory to produce $10,000,000,000 worth of Afrezza the company in a potential takeover target which may be why Mr. Mann probably decided to convert so much debt to equity at $2.59/share last week.
A "big-pharma" partnership could happen at any time.
Consider buying a few shares below $2.00 before the approval run-up begins.